Genentech, Inc. (DNA)

justahistorian (76.66) Submitted: 2/26/07 12:58 PM : Start Price: $85.63 DNA Score: -20.89

Genentech has some outstanding drugs, perhaps none better for revenue than Avastin. The drug has demonstrated efficacy in a number of different cancers and clinical trials to date have not shown that the drug should ever be stopped. Add to that the drug's cost $55,000/year for the most common use, and it should add up to strong revenue.

However, Genentech has recently introduced a new pricing program that has alienated some physicians. Of bigger concern is the Democratic congress that may use Genentech as the poster child for greedy pharmaceuticals during their push to get pharma reforms.

Report this Post Replies: 0 | Reply